What Happened

Celldex presented Phase 1 results for CDX-622, a bispecific antibody targeting soluble SCF and TSLP, at the EAACI 2026 meeting. The study showed rapid, durable mast cell depletion with no dose-limiting toxicities or serious adverse events.

Who Is Affected

This development impacts biotech investors, pharmaceutical companies, and healthcare providers focused on inflammatory diseases like asthma, allergic rhinitis, and food allergies. Celldex’s advancement also positions it as a leader in mast cell-targeted therapies.

Market Impact

• Celldex’s stock (CLDX) gained 4.37%, outperforming peers like COGT (+1.6%) and ARDX (-1.9%).
• The company’s mast cell-focused pipeline, including barzolvolimab and CDX-622, broadens its therapeutic reach.
• Positive clinical updates historically yield mixed stock reactions, but this announcement exceeded average gains.

What to Watch

Future milestones include Phase 1b asthma data, proof-of-concept studies in allergic rhinitis and food allergy, and progress in Phase 3 urticaria programs. Celldex’s dual-targeting approach could reshape treatment strategies for inflammatory diseases.